Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer - PubMed (original) (raw)
. 2013 Apr 1;190(7):3783-97.
doi: 10.4049/jimmunol.1201449. Epub 2013 Feb 25.
Affiliations
- PMID: 23440412
- DOI: 10.4049/jimmunol.1201449
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer
Jinpu Yu et al. J Immunol. 2013.
Abstract
Myeloid-derived suppressor cells (MDSCs) represent heterogeneous immunosuppressive cells in multiple cancer types and display potent immunosuppressive activity on T cells. We have shown the increased expression of IDO in breast cancer. Because IDO plays a pivotal role in immune tolerance via suppressing T cell function, the aim of this study was to investigate the expression of IDO in MDSCs in breast cancer and its role in MDSC-mediated inhibition of immune surveillance. The proportion of MDSCs with the phenotype of CD45(+)CD13(+)CD33(+)CD14(-)CD15(-) significantly increased in primary cancer tissues and patients' peripheral blood. IDO expression was significantly upregulated in MDSCs isolated from fresh breast cancer tissues (fresh MDSCs [fMDSCs]), which correlated with increased infiltration of Foxp3(+) regulatory T cells in tumors and lymph node metastasis in patients. fMDSCs inhibited IL-2 and anti-CD3/CD28 mAb-induced T cell amplification and Th1 polarization but stimulated apoptosis in T cells in an IDO-dependent manner. CD33(+) progenitors isolated from healthy donors' umbilical cord blood were cocultured with breast cancer cell line MDA-MB-231 cells to induce MDSCs. IDO expression was upregulated in induced MDSCs, which required phosphorylation of STAT3, but not STAT1. IDO was required for induced MDSCs' immunosuppressive activity on T cells, which was blocked by IDO inhibitor 1-methyl-L-tryptophan or STAT3 antagonist JSI-124. Consistently, increased STAT3 phosphorylation level was found in fMDSCs. Together, our findings suggest that STAT3-dependent IDO expression mediates immunosuppressive effects of MDSCs in breast cancer. Thus, inhibition of MDSC-induced T cell suppression by blocking IDO may represent a previously unrecognized mechanism underlying immunotherapy for breast cancer.
Comment in
Similar articles
- Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F, Zhao Y, Wei L, Li S, Liu J. Li F, et al. Cancer Biol Ther. 2018 Aug 3;19(8):695-705. doi: 10.1080/15384047.2018.1450116. Epub 2018 May 8. Cancer Biol Ther. 2018. PMID: 29621426 Free PMC article. - Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer.
Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H, Yan C, Yan F, Ren X. Yu J, et al. J Immunol. 2014 Sep 1;193(5):2574-86. doi: 10.4049/jimmunol.1400833. Epub 2014 Jul 25. J Immunol. 2014. PMID: 25063873 Free PMC article. Clinical Trial. - STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
Safarzadeh E, Mohammadi A, Mansoori B, Duijf PHG, Hashemzadeh S, Khaze V, Kazemi T, Derakhshani A, Silvestris N, Baradaran B. Safarzadeh E, et al. Front Immunol. 2021 Feb 19;11:613215. doi: 10.3389/fimmu.2020.613215. eCollection 2020. Front Immunol. 2021. PMID: 33679700 Free PMC article. - Amino acid metabolism related to immune tolerance by MDSCs.
Yang B, Wang X, Ren X. Yang B, et al. Int Rev Immunol. 2012 Jun;31(3):177-83. doi: 10.3109/08830185.2012.679989. Int Rev Immunol. 2012. PMID: 22587019 Review. - Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S, Bronte V, Mandruzzato S. Solito S, et al. J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review.
Cited by
- Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer.
Sarangi P. Sarangi P. Cancer Pathog Ther. 2023 Nov 7;2(4):246-255. doi: 10.1016/j.cpt.2023.11.001. eCollection 2024 Oct. Cancer Pathog Ther. 2023. PMID: 39371092 Free PMC article. Review. - Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
Ahmed EN, Cutmore LC, Marshall JF. Ahmed EN, et al. Cancers (Basel). 2024 Sep 18;16(18):3186. doi: 10.3390/cancers16183186. Cancers (Basel). 2024. PMID: 39335157 Free PMC article. Review. - Recent development of nanomaterials-based PDT to improve immunogenic cell death.
Ain QT. Ain QT. Photochem Photobiol Sci. 2024 Sep 25. doi: 10.1007/s43630-024-00638-y. Online ahead of print. Photochem Photobiol Sci. 2024. PMID: 39320675 Review. - Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.
Xiao Y, Li Y, Zhao H. Xiao Y, et al. Mol Cancer. 2024 Sep 18;23(1):202. doi: 10.1186/s12943-024-02113-9. Mol Cancer. 2024. PMID: 39294747 Free PMC article. Review. - Targeting amino acid-metabolizing enzymes for cancer immunotherapy.
Grobben Y. Grobben Y. Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024. Front Immunol. 2024. PMID: 39211039 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous